Journal of Diabetes Research / 2015 / Article / Tab 3

Research Article

Liraglutide, a Glucagon-Like Peptide-1 Analog, Increased Insulin Sensitivity Assessed by Hyperinsulinemic-Euglycemic Clamp Examination in Patients with Uncontrolled Type 2 Diabetes Mellitus

Table 3

Logistic regression analysis for the improvement of GIR (>0.5 mg/min/kg) in patients with uncontrolled type 2 DM.

Baseline variable Univariate regression Multivariate regression using forced inclusion model
OR95% CIOR95% CI

Age (per year)0.9970.932 to 1.0680.94
Gender (male)1.8050.377 to 8.6210.46
Body mass index (per 1.0)1.2410.925 to 1.6650.151.1610.847 to 1.5910.35
Hypertension (yes)4.1670.664 to 26.310.128
Dyslipidemia (yes)1.8350.432 to 7.7520.411
Current smoker (yes)0.3330.051 to 2.1790.251
Hemoglobin A1c (per 0.1; %) 1.1470.536 to 2.4550.724
Fasting plasma glucose (per 1.0; mg/dL)0.9960.974 to 1.0190.752
Fasting blood CPR (per 1.0; ng/mL)1.2650.615 to 2.6010.523
Duration of diabetes (per 1.0; years)0.9810.908 to 1.0590.623
Liraglutide-therapy (yes)5.9891.231 to 28.570.0245.0761.024 to 25.000.047

OR, odds ratio; CI, confidence interval; CPR, C-peptide radioimmunoreactivity.
Hosmer-Lemeshow = 0.19 in multivariate analysis.

We are committed to sharing findings related to COVID-19 as quickly as possible. We will be providing unlimited waivers of publication charges for accepted research articles as well as case reports and case series related to COVID-19. Review articles are excluded from this waiver policy. Sign up here as a reviewer to help fast-track new submissions.